Cord blood cell therapy alters LV remodeling and cytokine expression but does not improve heart function after myocardial infarction in rats by Rabald, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
Cord blood cell therapy alters LV remodeling and cytokine expression but
does not improve heart function after myocardial infarction in rats
Rabald, S; Marx, G; Mix, B; Stephani, C; Kamprad, M; Cross, M; Boltze, J; Briest, W; Zimmer, H;
Deten, A
Abstract: OBJECTIVE: In this study the ability of unrestricted somatic stem cells (USSC) and mononu-
clear cord blood cells (MN-CBC) was tested to improve heart function and left ventricular (LV) remod-
eling after myocardial infarction (MI). METHODS: The cells were delivered by i.v. or intramyocardial
injections in rat models of MI by permanent coronary artery occlusion and by ischemia/reperfusion (I/R)
injury. Heart function and remodeling was followed by recurrent echocardiography over 8 or 12 weeks
after which catheterization was performed. RESULTS: Although injected labeled cells could be observed
within the myocardium for up to 6 d, there was no sign of cardiac regeneration 8 or 12 weeks after
MI. However, the mRNA expression of components of the extracellular matrix was attenuated in the
infarct scar 12 weeks after MI and cell injection. Additionally, the expression of interleukin (IL)-6 but
not of IL-1 beta increased at the site of injury and the adjacent border-zone 12 weeks after I/R and
USSC-injection. However, these effects did not translate into improved heart function or attenuated LV
dilatation. CONCLUSION: These data indicate that cord blood cell implantation after MI acts through
paracrine mechanisms to modify remodeling rather than myocyte regeneration. The role of myofibrob-
lasts and the optimal conditions of cell application need to be determined to translate these mechanisms
into functional improvement.
DOI: 10.1159/000129632
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-4584
Published Version
Originally published at:
Rabald, S; Marx, G; Mix, B; Stephani, C; Kamprad, M; Cross, M; Boltze, J; Briest, W; Zimmer, H; Deten,
A (2008). Cord blood cell therapy alters LV remodeling and cytokine expression but does not improve
heart function after myocardial infarction in rats. Cellular Physiology and Biochemistry, 21(5-6):395-408.
DOI: 10.1159/000129632
395
Original Paper
Cell Physiol Biochem 2008;21:395-408 Accepted: December 06, 2007Cellular Physiology
and Biochemistry
Copyright © 2008 S. Karger AG, Basel
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2008 S. Karger AG, Basel
1015-8987/08/0216-0395$24.50/0
Accessible online at:
www.karger.com/cpb
Cord Blood Cell Therapy Alters LV Remodeling
and Cytokine Expression but does not Improve
Heart Function after Myocardial Infarction in Rats
Steffen Rabald1, Grit Marx2, Brigitte Mix2, Caspar Stephani3, Manja
Kamprad4, Michael Cross5, Johannes Boltze6, Wilfried Briest7, Heinz-
Gerd Zimmer2 and Alexander Deten8
1Department of Surgery, Leipzig University, 2Carl-Ludwig-Institute of Physiology, Leipzig University,
3Interdisciplinary Center for Clinical Research, Leipzig University, 4Institute of Immunology and
Transfusion Medicine, Max Burger Research Center, Leipzig University, 5Department of Hematology/
Oncology, Leipzig University, 6Fraunhofer-Institute for Cell Therapy and Immunology, Leipzig, 7Laboratory
of Cardiovascular Sciences, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224,
USA, 8Institute of Veterinary Physiology, Vetsuisse Faculty University of Zurich
Alexander Deten, MD
Fraunhofer-Institute for Cell Therapy and Immunology
Deutscher Platz 5e, D-04103 Leipzig, (Germany)
Tel. +49 (0)341 25810, Fax +49 (0)341 25809
E-Mail Alexander.Deten@izi.fraunhofer.de
Key Words
Myocardial infarction • Heart function, remodeling •
Cell therapy, animal model
Abstract
Objective: In this study the ability of unrestricted so-
matic stem cells (USSC) and mononuclear cord blood
cells (MN-CBC) was tested to improve heart function
and left ventricular (LV) remodeling after myocardial
infarction (MI). Methods: The cells were delivered by
i.v. or intramyocardial injections in rat models of MI
by permanent coronary artery occlusion and by
ischemia/reperfusion (I/R) injury. Heart function and
remodeling was followed by recurrent echocardio-
graphy over 8 or 12 weeks after which catheteriza-
tion was performed. Results: Although injected labeled
cells could be observed within the myocardium for up
to 6 d, there was no sign of cardiac regeneration 8 or
12 weeks after MI. However, the mRNA expression of
components of the extracellular matrix was attenu-
ated in the infarct scar 12 weeks after MI and cell
injection. Additionally, the expression of interleukin
(IL)-6 but not of IL-1β increased at the site of injury
and the adjacent border-zone 12 weeks after I/R and
USSC-injection. However, these effects did not trans-
late into improved heart function or attenuated LV
dilatation. Conclusion: These data indicate that cord
blood cell implantation after MI acts through paracrine
mechanisms to modify remodeling rather than myo-
cyte regeneration. The role of myofibroblasts and the
optimal conditions of cell application need to be de-
termined to translate these mechanisms into func-
tional improvement.
Introduction
After acute myocardial infarction (MI) had occurred,
the basic pathology is characterized by irreversible and
massive loss of the cardiomyocytes, which is eventually
replaced by fibrous non-contractile cells to form scar tis-
sues. Although the myocytes in the surviving myocar-
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dium undergo hypertrophy this is often not sufficient to
preserve heart function. As a consequence, congestive
heart failure develops even though the recent advances
in the therapeutic approaches, including pharmacological
and interventional therapies, and cardiovascular surgery
provide some improvement. As a newly developed strat-
egy, cellular cardiomyoplasty, which involves the implan-
tation of healthy cells into the damaged myocardium, of-
fers the promise to replace the lost cells.
Transplantation of cells, including cardiomyocytes
[1, 2], skeletal myoblasts [3], bone marrow cells [4, 5],
smooth muscle cells [6], and embryonic stem cells [7]
has been reported to be of potential therapeutic value for
the treatment of damaged myocardium in animal models.
These transplanted cells may replace infarcted myocar-
dium and increase the number of functional
cardiomyocytes, limit the scar expansion, and reduce post-
infarction heart failure [8]. Also, transplanted cells may
contribute to the revascularization process and enhance
myocardial angiogenesis [8]. They also may serve as a
platform for therapeutic gene transfer to the myocardium
[9]. The beneficial effect of cell transplantation on car-
diac functions in preclinical studies has led to several clini-
cal trials [10].
Mesenchymal stem cells (MSCs) isolated from adult
bone marrow have shown a great potential for cell therapy
because these cells possess pluripotent capabilities [11,
12], proliferate rapidly, can ´self-renew´, induce angio-
genesis, and differentiate into myogenic cells [13-15].
MSCs can be isolated easily from a variety of sources,
have genetic stability, and carry less immunological or
ethical concerns. Hence, they were considered very suit-
able candidate donor cells for stem cell therapy and tar-
get cells for gene transfer [16, 17]. Recently, a pluripo-
tent stem cell population with high proliferative potential,
unrestricted somatic stem cell (USSC), was isolated from
the endothelium/subendothelium layer of the human um-
bilical cord blood [18] that is morphologically and
immunophenotypically similar to those MSCs isolated
from bone marrow [19, 20]. Hence, USSCs have been
suggested to be an earlier cell type than multipotent MSCs,
possibly representing the precursor cells for MSCs as a
comparison of the differentiation potentials of USSCs [18]
and MSCs [21] has shown. In vitro and in vivo studies
demonstrated that the USSCs have the potential to dif-
ferentiate into osteoblasts, chondrocytes, adipocytes, neu-
rons, and myocytes [18]. Moreover, in a sheep model,
the application of USSCs did not induce detectable tumors
in a long-term study after transplantation [18]. There-
fore, USSCs could be highly promising precursor cells
for cardiac implantation after a myocardial infarction.
This study was performed to test the ability of
USSCs to improve heart function and left ventricular (LV)
remodeling after MI. The cells were delivered by
intramyocardial injections in rat models of MI by perma-
nent coronary artery occlusion and by ischemia/
reperfusion (I/R) injury. Additionally, mononuclear cord
blood (MN-CBCs) cells without further separation were
tested and the effects compared.
Materials and Methods
Animal model
Myocardial infarction was induced in male (3.5 months of
age and 291±4 g of body weight at the beginning of the study)
spontaneously hypertensive rats (SHR, Charles River) and fe-
male (3 month of age and 242±14 g of body weight at the begin-
ning of the study) Sprague-Dawley rats (SD, Charles River) by
ligation of the left anterior descending coronary artery (LAD)
as previously described [22]. For the I/R experiments which
were done only in the SD rats, a small ring (cord diameter 1 mm)
was placed under the ligature. After 60 min of occlusion, the
rats were again anesthetized, the chest was opened and both,
the ring and the ligature were removed. Successful reperfusion
was verified by Evans blue infusion in pilot experiments (not
shown), but became also momentarily overt by the color change
of the previously ischemic myocardium from pearl grey to pink.
After 24 h the surviving SHR (n=46) were randomly se-
lected to receive either cells (MI+MN-CBC, 3x106 cells in 500 µl
medium, n=23) or medium (MI-CTRL, n=23) via a tail vein. The
surviving SD rats (n=47) were also randomly selected after 24 h
for direct intramyocardial injection of either cells (each 1x106
cells, n=14 for MN-CBCs and n=15 for USSCs) or medium
(n=18). In the I/R experiments, the rats were randomly selected
to either receive cells (1x106 USSCs, n=9) or medium (n=9) by
direct intramyocardial injection at the time of reperfusion (Tab.
1). The intramyocardial injections were performed at two sites
(10 µl each) at the mid-anterior and mid-lateral left ventricular
wall using a precision syringe (22G, Hamilton), the needle was
equipped with additional tubing as retardant. All rats in the I/R
sub-study received additional immune-suppressive therapy
with Cyclosporine (Sandimmun Neoral®, Novartis, Germany,
15 mg/kg/d) beginning the day before surgery.
Twelve additional SHR were used to track injected CFSE-
labeled cells after 6 and 24 h (n=4 for MN-CBCs and n=2 for
medium at each time-point). Also 16 additional SD rats were
analyzed for injected labeled cells immediately (MI, n=4), 1 d
(MI, n=3) and 6 d (each n=3 for both, MI and I/R) after injec-
tion. Medium-treated MI hearts at 1 d after injection served as
controls (n=3).
Sham-operated animals (n=24 for SHR and n=18 for SD)
underwent the same procedure except that no ligation was per-
formed. Also the groups of sham operated animals were di-
vided into sub-groups to receive either cells or medium. These
groups were combined for subsequent comparison with MI
Rabald/Marx/Mix/Stephani/Kamprad/Cross/Boltze/Briest/Zimmer/
Deten
Cell Physiol Biochem 2008;21:395-408
397
(I/R) rats, since there were no statistically significant differ-
ences between the differently treated sham groups. The inves-
tigation conforms with the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996) and was approved
by the appropriate State agency of Saxony.
Isolation of human cord blood cells
Human cord blood was collected from umbilical cord vein
of full-term pregnancies, after informed consent. The investi-
gation conforms with the principles outlined in the Declaration
of Helsinki. Mononuclear cord blood cells (MN-CBCs) were
isolated by Ficoll-Hypaque density gradient separation fol-
lowed by erythrocyte lysing in distilled water. MN-CBCs were
cryopreserved in 8% dimethyl sulphoxide (DMSO) and 92%
fetal calf serum (FCS) at –196°C (liquid nitrogen). After thaw-
ing by stepwise dilution in RPMI 1640 (PAA Laboratories) and
washing by DNase-containing buffer (DNase I, Roche), the
cells were analyzed by flow cytometry and used for transplan-
tation. To isolate unrestricted somatic stem cells (USSCs), the
mononuclear cell fraction was isolated by Ficoll-Hypaque den-
sity gradient separation and plated at 4-6 x106 cells/ml and in-
cubated at 1% O2 in cell culture flasks (Greiner Bioscience).
Medium contained 70 % low glucose (5mM) DMEM (Sigma),
30 % FCS (Pan Biotech) and was changed every 7 days until
formation of colonies of adherent cells was observed as previ-
ously described [18]. Cells were harvested after reaching
confluency and further expanded with a lower concentration
of Dexamethason at a density of 4x104 cells/cm2. Only USSCs
from passage 5-7 were used for experiments.
Flow Cytometry
MN-CBCs were analyzed for the cell surface antigens
CD45, CD34, CD133 and the homing receptor CXCR4 compared
to isotype controls in order to estimate the relative number of
stem cell/progenitor population. CD45-PC7 and CD34-APC
antibodies were purchased from Beckman Coulter (Immunotech)
while the CD133-PE antibody was obtained from Miltenyi
Biotech. The CXCR4 antibody was purchased from R&D Sys-
tems and the secondary goat-anti-mouse-FITC antibody from
DAKO. Cells were incubated with antibodies 30 minutes at 4°C
and washed twice. After fixation in 3% formaldehyde the cells
were analyzed using FACSCalibur and CellquestPro software
(Becton Dickinson) according to the manufactures protocol.
The gating strategy for the hematopoietic stem cells was ac-
cording to the ISHAGE guidelines [23].
USSCs were analyzed for the cell surface antigens CD13,
CD34, CD90 (all Becton Dickinson), and CD105 (Serotec) com-
pared to the isotype control. Cells were incubated with anti-
bodies for 40 minutes at 4 °C and washed once with PBS.
The cells were resuspended in PBS and immediately analyzed
using FACSCalibur and CellquestPro software (Becton
Dickinson).
Cell labeling
For a simple and rapid recovery the cells were labeled
with 5 µM 5,6-Carboxyfluoresceindiacetat-succinimidylester
(CFSE, Molecular Probes). The cells were incubated in RPMI
with 1% CFSE for 10 minutes at 37°C and then washed twice
with RPMI and 10% FCS. Cells were resuspended in RPMI
1640 / 1% FCS, analyzed by flow cytometry and used for trans-
plantation.
Echocardiography
Echocardiographic measurements were performed with a
commercially available ultrasound system (GE Vivid 7 equipped
with an 11.5 MHz sector scan probe, GE Healthcare). Examina-
tions were performed in spontaneously breathing animals, un-
der 1.5 % isofluran anesthesia, in left lateral decubitus posi-
tion. Parasternal short axis view was recorded at the largest
round diameter of the left ventricle. For recording of the con-
trast enhanced loops, a tail vein was punctured, and contrast
medium (Optison®, GE Healthcare) was injected after adjust-
ing the apical view and reducing the ultrasound beam power.
Criteria for all apical views were to display the mitral valve
opening and the LV in its longest cross section with minimal
displacement effects on wall thickness. Within these criteria
the four chamber view was identified as the view with the larg-
est cross-section of the right ventricle (RV). The two chamber
view was taken pragmatically orthogonal from the four cham-
ber view. Additionally, a standard record of established Dop-
pler measurements was taken.
Offline analyses from the digital raw data were performed
on a PC using ultrasound analysis software (EchoPac PC, GE
Healthcare). All measurements were done in 3 to 5 consecutive
heartbeats. Left ventricular end systolic (LVESV) and end
diastolic (LVEDV) volume were measured by the software’s
internal algorithm (SIMPSON, biplane) from the paired apical
views. Ejection fraction (EF) was calculated by EF=(LVEDV-
LVESV)/LVEDV. From short axis view, left ventricular end
systolic (LVESA) and end diastolic (LVEDA) area were meas-
ured. Fractional area change (FAC) was calculated by
FAC=(LVEDA-LVESA)/LVEDA.
Hemodynamic measurements
At the end of the observation periods, left and right heart
function was measured in closed-chest spontaneously breath-
ing rats anesthetized with thiopental sodium (Trapanal® 80
Table 1. Study design and animal numbers. Total numbers of
animals and in each group; in brackets: survived the first day
after surgery; in parenthesis: survived observation period; MI:
myocardial infarction; I/R ischemia/reperfusion; CTRL: injected
with medium; MN-CBCs: injected with human mononuclear cord
blood cells; USSCs: injected with human unrestricted somatic
stem cells.
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mg/kg i.p., Byk Gulden) using ultraminiature catheter pressure-
transducers (3F, Millar Instruments Inc.) [22]. Cardiac output
was measured by the thermodilution method (Cardiomax-IIR,
Columbus Instruments) [24].
Tissue collection and infarct size measurement
After the hemodynamic measurements had been ob-
tained, the hearts were arrested in diastole by KCl injection
and rapidly excised. The hearts from the SHR sub-study were
fixed in 4% paraformaldehyde, cut into 5 transversal sections
and photographed. The MI size was calculated as ratio of the
infarcted segment to the total LV perimeter averaged between
endocardial and epicardial measurements using the ImageJ
1.33k software (NIH), and the average MI was expressed as a
percentage of total LV perimeter [25, 26]. Additionally, seg-
ments at mid-papillary level were paraffin-embedded, and sec-
tioned at 8 µm. The hearts from the SD rats were transversally
cut in two halves approximately at mid-papillary level (site of
largest infarct extension). The apical parts were used for histo-
logical analyses. From the basal part, the RV was trimmed away
Fig. 1. FACS analysis of MN-CBCs for
CD45, CD34, and CD133 (upper panels) and
of USSCs for CD90, CD105, CD13, and CD34
(lower panels with isotype controls in the
middle column) isolated from human cord
blood. The gating strategy was according
to the ISHAGE guidelines.
and the infarct scar was excised as well as a 2-3 mm border zone
adjacent to the infarct scar. All tissue pieces were snap-frozen
in liquid nitrogen for later analyses.
In additional experiments the hearts were harvested im-
mediately as well as 6 h, 24 h and 6 d after injection of labeled
cells or medium. The hearts were embedded in O.T.C. com-
pound, cryopreserved in melting methylbutan, and subse-
quently sectioned at 7 µm. After DAPI-staining of the nuclei
the sections were directly analyzed under a fluorescence-mi-
croscope (Zeiss Axioskop) and photographed.
Immunohistochemical analysis
The following antibodies were used: anti-smooth muscle
actin (SMA; mouse monoclonal, dilution 1:1.000; Boehringer
Mannheim), and desmin (rabbit polyclonal, dilution 1:500;
PharMingen). Immunohistochemical analysis was performed
according to the recommendations supplied by the manufac-
turer. Sections known to stain positively were included in each
batch and negative controls were performed by replacing the
primary antibody with serum (Sigma-Aldrich).
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RNase Protection Assay (RPA)
Total RNA isolation and RNase protection assay (RPA)
were performed as previously described [22, 27].
Statistical Analysis
The data are expressed as mean (SD). A Kruskall-Wallis
ANOVA on ranks was used for multigroup comparison subse-
quently utilizing multiple comparison procedure according to
Dunn’s method (SigmaStat 3.10, SPSS Corp.). Cumulative sur-
vival was analyzed by Kaplan-Meier-Plot including overall
comparison according to Mantel-Cox, Breslow, and Tarone-
Ware (SPSS 13.0 for Windows, SPSS Corp.) A value of p < 0.05
was considered statistically significant.
Results
Cell characterization
Nearly all of the alive, isolated mononuclear cord
blood cells were positive for CD45. Only 0.7±0.09 % of
those (medium intense CD45+) cells were also positive
for CD34, but 79.4±2.2 % of the CD45+/CD34+ cells
stained for CD133 (Fig. 1). Moreover, after
cryopreservation 30.6±16.2 % of the CD34+ cells also
expressed the stem cell receptor CXCR4. Nearly all of
the cultured USSCs were positive for CD105 and CD13
surface antigens and, also for CD90. However, staining
for CD34 was weak (Fig. 1).
Survival and infarct size
The mortality within the first 24 h after coronary
artery occlusion in the SHR sub-study was 19% (14/72).
The animals which had survived for 24 h, were randomly
selected to receive either MN-CBCs or medium. Twelve
rats were used to track the injected cells after 6 and 24 h
while the remaining 46 rats were followed for 8 weeks.
During this observation period the cumulative survival of
the MI+MN-CBC group (13/23) was not significantly dif-
ferent from that of the medium-treated MI-CTRL group
(14/23) (Fig. 2, left). There was also no difference in the
infarct size (Fig. 2, right). None of the sham-operated
rats died.
The mortality within the first 24 h after coronary
artery occlusion in the SD MI sub-study was 27% (21/
78). The surviving animals were also randomly selected
to receive either cells or medium. Ten rats were used to
track the injected cells while the remaining 47 rats were
followed for 12 weeks (Tab. 1). During this observation
period 2 of the MN-CBC-treated, but none of the me-
dium-treated rats died. Two more rats (each 1 of the
MN-CBC-treated and 1 of the USSC-treated rats) died
during the night after last echocardiography, but before
final hemodynamic measurements. Statistics of cumula-
tive survival was not done due to the small numbers. Also,
MI size was not measured, since a part of the hearts was
used for molecular biological analyses. None of the I/R
rats or of the sham-operated rats died.
Echocardiography
Echocardiography was performed in the SD sub-
studies only. Successful induction of MI was confirmed
by an echocardiographically akinetic LV free wall in all
animals a few hours after surgery (details not shown).
Severely impaired heart function became overt by greatly
reduced EF (and FAC) 2 weeks after MI (Fig. 3).
Thereafter, it only slightly decreased over time. LV di-
mensions at both, end-diastole and end-systole, increased
dramatically 2 weeks after coronary artery occlusion.
Thereafter, they further increased, but less pronouncedly.
Reduced LV pump function was also indicated by an
Fig. 2. Cumulative
survival (left) and inf-
arct-size (right) 8
weeks after myocar-
dial infarction (MI)
and medium (CTRL) or
mononuclear cord
blood cell injection
(MN-CBC).
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increased size of the LA. VTIAo, on the other hand, de-
creased only slightly and this decrease was statistically
significantly different from sham-operated rats 12 weeks
after surgery (Fig. 3). Most importantly, these changes
were observed in all MI rats, the cell-injected rats being
indistinguishable from the medium-injected MI-CTRLs.
FAC decreased severely 2 weeks after I/R and fur-
ther deteriorated over time thereafter (Fig. 3, right col-
umn). Moreover, LV dimensions increased 2 weeks af-
ter I/R, but this increase was less pronounced compared
to MI. VTIAo was not statistically significantly reduced
after I/R. Importantly again, these changes were not dif-
ferent between USSC-injected and medium-injected I/R
rats.
Hemodynamic measurements
Heart function could not be measured in all rats,
since in all MI-groups 2 rats died shortly after thiopental
injection for anesthesia. Hemodynamic data revealed
severely depressed heart function after MI. The LV
systolic pressure (LVSP), LVdP/dtmax and LVdP/dtmin
severely decreased after MI while LV end-diastolic pres-
Fig. 3. Summary of
echocardiographic data over
12 weeks after permanent
coronary artery occlusion
(MI, left and middle column)
or ischemia/reperfusion (I/R,
right column). LVED(S)V(A)
left ventricular end-diastolic
(-systolic) volume (area); EF
ejection fraction; FAC frac-
tional area change; VTI ve-
locity time integral. Data are
mean±SD; * p<0.05 for all MI-
groups vs sham (data for 6
weeks I/R were calculated vs
the mean of 4 and 8 weeks
sham).
sure (LVEDP) and τ increased (Tab. 2). Total peripheral
resistance (TPR) also declined, but mainly due to the re-
duced mean arterial pressure, since cardiac output
decreased significantly only in the SHR after MI. Im-
paired pump function of the LV became also overt by
increased parameters of the RV. Importantly, all these
parameters of deteriorated LV and elevated RV function
were not significantly different between medium-injected
and cell-injected MI-rats, except for TPR in the SD MI-
sub-study.
The hemodynamic consequences were less profound
12 weeks after I/R (Tab. 2). LVSP remained normal while
LVEDP increased only slightly. Consequently, RV func-
tion was comparable to sham-operated rats. The param-
eters of LV contractility and relaxation, on the other hand,
were significantly impaired after I/R. This, however, was
not different between USSC- and medium-injected rats.
Cell tracking
CFSE-labeled cells were detected by green fluo-
rescence (Fig. 4). They were observed after i.v. injec-
tion in paravasal regions of the border zone adjacent to
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Table 2. Hemodynamic characterization
8 (SHR) or 12 weeks (SD) after sham-op-
eration, myocardial infarction, ischemia/
reperfusion or MI (I/R) and
intramyocardial cell injection. Data are
mean (SD); MI myocardial infarction; I/
R ischemia/reperfusion; MI(I/R)-CTRL
MI(I/R) sham-treated with medium;
MI+MN-CBCs; MI treated with human
mononuclear cord blood cells; MI(I/
R)+USSCs MI(I/R) treated with human
unrestricted somatic stem cells; HR heart
rate; SAoP and DAoP aortic systolic and
diastolic pressure, respectively; MAP
mean arterial pressure; AoPP aortic pulse
pressure; CO cardiac output; CI cardiac
index; SV stroke volume; TPR total pe-
ripheral resistance; SP systolic pressure;
EDP end-diastolic pressure; dP /dt max/
min maximal rate of rise/fall in ventricular
pressure; τ time constant of isovo-
lumetric relaxation; τ (rel) τ normalized to
cardiac cycles length; MVO2 triple prod-
uct of SP*dP/dt max*HR indicative for
myocardial. oxygen consumption;
* p < 0.05 vs. corresponding sham;
† p < 0.05 vs. corresponding MI-CTRL.
Cord Blood Cells after Myocardial Infarction Cell Physiol Biochem 2008;21:395-408
402
Fig. 4. Tracking of CFSE-labeled cells.
Green, red, blue fluorescence, and merge
in the border-zone 48(24) h after MI and
i.v. cell (A-D) or medium (E-F) injection. I
and J Green fluorescence and HE stain-
ing of a consecutive section from the
border-zone 48(24) h after MI and i.v. cell
injection. K Amidoblack-injections to
verify intramyocardial delivery. HE stain-
ing and green fluorescence immediately
(L and M) or 6 d (N) after I/R and
intramyocardial injections.
Fig. 5. Histological overviews (Mason´s trichrome) after MI
and I/R. A SHR sham; B SHR MI-CTRL; C MI+MN-CBCs; D/G
SD MI-CTRL; E/H SD MI-MC-CBCs; F/I SD MI+USSCs; J SD
sham; K SD I/R-CTRL; L SD I/R+USSCs.
Fig. 6. Overviews (2 upper rows) and higher magnification (2
lower rows) of Mason´s trichrome (left) and consecutive anti-
SMA (middle) and anti-desmin (right) staining 12 weeks after
MI and medium (A-C and G-I) or MN-CBC (D-F and K-M)
injection.
the infarct area (identified as infiltration zone in HE stained
serial sections) 6 and 24 h after cell injection (Fig. 4A-J).
Green spots were also detected in medium-injected MI-
CTRL-hearts (Fig. 4E-H). However, these spots showed
also red fluorescence and could not be assigned to a nu-
cleus. Therefore, they represent non-specific auto-fluo-
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rescence. Successful intramyocardial cell injection was
verified immediately after injection (Fig. 4K-M). Also 6
d after injection, labeled cells could be detected in the
hearts, but apparently in smaller numbers (Fig. 4N).
Histological and Immunohistochemical analyses
All sections of the MI-hearts revealed typical
changes for old infarcts with a subendocardial layer as
well as patchy subepicardial amounts of surviving
myocytes (Fig. 5). Despite similar infarct-sizes and no
obvious signs of regeneration at the site of former injury,
Mason’s trichrome overview staining showed islets of
red-stained cell bodies within the blue-stained collagen-
ous scar (Fig. 6, left column). Immunohistochemical analy-
sis revealed that those cells were positive for α-SMA
but negative for desmin (Fig. 6, middle and right column).
Moreover, neither occurrence nor characteristics of those
cell islets were different between cell-injected and me-
dium-injected hearts.
Expression of components of the extracellular
matrix and of cytokines
The mRNA-expression of some major components
of the extracellular matrix (ECM) namely collagen I, col-
lagen III, the collagen chaperon colligin (also known as
Hsp47), matrix-metalloproteinase (MMP)-2 and tissue
inhibitor of matrix-metalloproteinases (TIMP) 2 substan-
tially increased after MI (Fig. 7). This increase was most
pronounced in the infarct area, but was also observed in
the border-zone adjacent to the MI as well as in the non-
infarcted LV and RV. Interestingly, these changes were
significantly attenuated in both, the MN-CBC and the
USSC-treated hearts. However, this was observed only
in the infarct area in which the ECM expression in the
cell-treated hearts after MI was comparable to that after
I/R. In general, ECM expression also increased after I/
R, but to a lesser extent and only in the area of injury and
in the adjacent border-zone. However, the increase in
ECM expression 12 weeks after I/R was not different
Fig. 7. Summary of mRNA expression of extracellular matrix components (left) and representative RPA (right). 1 sham LV; 2 sham
RV; 3 MI-CTRL; 4 MI+MN-CBCs; 5 MI+USSCs; 6 I/R-CTRL; 7 I/R+USSCs. Data are normalized to the acidic ribosomal phospho-
protein (ARPP) and shown as mean±SD. * p<0.05 vs corresponding sham; † p<0.05 vs MI-CTRL.
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between the USSC-treated and the medium-treated
hearts.
Also ANF expression was induced after MI and I/
R (Fig. 7). The most pronounced increase was observed
after MI in the RV, in which it was absent after I/R.
However, ANF expression was not influenced by cell-
treatment, except for a slight but statistically significant
reduction in the non-infarcted LV of the MN-CBS-treated
rats.
The mRNA-expression of the TGF-β isoforms was
induced after MI (Fig. 8). TGF-β1 expression increased
predominantly in the infarct area after permanent coro-
nary artery occlusion. This increase was attenuated in
the rats treated with MN-CBCs, but not in the rats treated
with USSCs. The induction in TGF-β3 was similar to that
of TGF-β1, but generally more marked. Again, the most
pronounced increase occurred in the infarct area after
permanent coronary artery occlusion and was attenuated
in the MN-CBC treated rats, but not after treatment with
USSCs. Also TGF-β2 mRNA expression was induced
after injury. In contrast to the other isoforms, the increase
in TGF-β2 was not reduced after MN-CBC therapy but
slightly more pronounced, although this did not reach sta-
tistical significance. Moreover, the induction of TGF-β2
was more pronounced after I/R and in the border zone
adjacent to the infarct area after permanent coronary
artery occlusion (Fig. 8).
The mRNA-expression of interleukin (IL)-1β and
IL-6, but not of tumor necrosis factor-α was induced in
the area of injury and in the adjacent border-zone, but not
in the non-infarcted LV and RV (Fig. 9). Moreover, the
increase in IL-1β was more pronounced after MI com-
pared to I/R, but not influenced by cell application. In
contrast, the increase in IL-6 expression was compara-
ble after MI and I/R. Moreover, it was significantly pro-
nounced in both, the injured area and the adjacent bor-
der-zone of the USSC-treated hearts. However, this was
observed after I/R but not MI.
Discussion
After intramyocardial injection of both, MN-CBCs
and USSCs, into the site of injury 24 h after permanent
coronary artery occlusion, the mRNA expression of com-
ponents of the ECM was attenuated in the scar after 12
weeks (Fig. 7). This was accompanied by a reduced in-
duction of TGF-β1 and TGF-β3 expression after MN-
CBC, but not after USSC treatment (Fig. 8). Addition-
ally, the expression of IL-6 but not of IL-1β was increased
Fig. 8. Summary of mRNA expres-
sion of TGF-β-isoforms (left) and rep-
resentative RPA (right). 1 sham LV; 3
MI-CTRL; 4 MI+MN-CBCs; 5
MI+USSCs; 6 I/R-CTRL; 7 I/
R+USSCs. Data are normalized to the
acidic ribosomal phosphoprotein
(ARPP) and shown as mean±SD; *
p<0.05 vs corresponding sham; †
p<0.05 vs MI-CTRL.
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Fig. 9. Summary of mRNA expression
of cytokines (left) and representative
RPA (right). 1 sham LV; 2 sham RV; 3 MI-
CTRL; 4 MI+MN-CBCs; 5 MI+USSCs; 6
I/R-CTRL; 7 I/R+USSCs. Data are nor-
malized to the mRNA of the ribosomal
protein L32 and shown as mean±SD; *
p<0.05 vs corresponding sham; † p<0.05
vs I/R-CTRL.
at the site of injury and the adjacent border-zone 12 weeks
after I/R and USSC-injection (Fig. 9). However, these
effects did not translate into improved heart function or
attenuated LV dilatation (Tab. 2 and Fig. 3). Moreover,
there was no sign of regeneration (Fig. 5 and 6).
The effect of stem and progenitor cells after MI is
still controversial. In this study, USSCs as precursors of
MSCs with remarkable pluripotent capabilities [18, 28]
and, therefore, as promising candidates were compared
with MN-CBCs in regard to their effectiveness. The lat-
ter have recently been shown to exert beneficial func-
tional effects in a very similar setup of experimental stroke
in SHR [29, 30]. The lack of any obvious myocardial
regeneration is in line with previous reports showing that
myocyte transdifferentiation of various progenitor cells
originating from the bone marrow (BM) is a very rare
event, if any [31-35]. Moreover, intracoronary injection
of USSCs 7 d after I/R in a porcine model did not attenu-
ate MI-induced LV remodeling or ameliorate global and
regional LV dysfunction [36]. An earlier study, however,
reported that direct injection of USSCs into the border
zone of the infarct area 4 weeks post-MI in a porcine
model of permanent occlusion resulted in significant im-
provement of ejection fraction compared to medium-
treated controls at 8 weeks post-MI [37]. Also in rats
direct injection of MN-CBCs at 1 week after permanent
coronary artery occlusion significantly improved LV func-
tion 4 weeks after treatment [38]. Additionally, intrave-
nous injection of MN-CBCs 1 day after permanent coro-
nary artery ligation in mice was reported to reduce inf-
arct size [39].
It is, however, difficult to reconcile the data of the
present study with the findings of the previous reports. A
number of factors like pre-selection and pre-treatment
of the cells, time and route of application, isolation and
storage method, and the experimental setup might be of
influence. The timing of cell injection cannot explain the
observed lack of benefit on LV remodeling, function or
infarct size, since previous studies showed beneficial ef-
fects of cord blood cell injection as early as 20 min, 60
min, or 1 day [39-41] after coronary ligation, but also as
late as 1 or 4 weeks after ligation [37, 38]. The results of
these previous studies were observed 3-4 weeks after
MI, also indicating that the 8-12 week follow-up period
was sufficient to allow detection of an effect of cell trans-
plantation.
Cord blood cells are assumed to possess immune-
privileges and are supposed to be hypo-immunogenic [42].
Furthermore, in a previous study labeled USSCs were
detected in the infarct zone 4 days after injection with
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and without immunesuppression, suggesting the absence
of hyper-acute rejection [36]. Since hypoimmunogenicity
of the umbilical cord blood derived cells is still question-
able and, also, may change in case differentiation takes
place, an additional immunosuppressive therapy was ap-
plied in the I/R sub-study to exclude the possibility that
the lack of functional effects was due to rejection.
For the experiments in hypertensive rats, the cells
were injected intravenously after permanent coronary
occlusion. The low level of engraftment of these cells
into the injured adult heart after tail vein infusion may not
be surprising, because the occluded artery makes it diffi-
cult for the injected cells to reach the infarcted myocar-
dium. This problem is compounded by the fact that intra-
venously injected cells are likely to be sequestered in
various organs. However, labeled cells were clearly de-
tected in paravasal regions of the border zone adjacent
to the infarct area (Fig. 4), but not quantified. A much
higher number of cells was detected after direct cell in-
jection, but considerably decreased after 6 d (Fig. 4). Only
freshly cultured USSCs were used in this study, but
cryopreserved MN-CBCs. Although a small portion of
the cryopreserved cells is not viable after thawing, the
majority of these cells can unrestrainedly be cultured (de-
tails not shown). To generally minimize cell damage dur-
ing injection, a canula with a large diameter was used
(22G). It can also not completely be ruled out that CFSE
labeling impairs the capabilities of the cells. In pilot stud-
ies, however, it did not affect proliferation and viability of
cultured MN-CBCs (details not shown). Nonetheless,
unlabeled cells were used for the long-term experiments,
since after that time also other factors like fusion or loss
of CFSE during proliferation might complicate possible
interpretations. Since the histological examination revealed
typical changes for old infarcts and, more importantly,
the cell-treated hearts were indistinguishable from the
medium-treated controls, further staining for typical car-
diac transcription factors (GATA4, MEF2) was not per-
formed. Therefore, it can not completely be ruled out
that a very small number of the injected cells could be
able to differentiate and remained at the site of injury.
This would be in line with a previous study in pigs report-
ing only a few of the injected USSCs after 4 weeks [36].
Moreover, the injected USSCs did not transdifferentiate
into a cardiomyocyte or endothelial phenotype since they
were negative for Troponin and vWF, but were still CD45
positive.
It has also been hypothesized that enhanced
neoangiogenesis after BM cell application might contrib-
ute to improved ventricular function after MI. From re-
cent studies, however, involvement of BM derived cells
in peri-infarct or hypoxia-induced angiogenesis has been
questioned [34, 43], although this is very likely for
endothelial progenitor cells. Neoangiogenesis in scar tis-
sue might be important for remodeling, but was not
analyzed in this study, since myocardial functional im-
provement directly caused by enhanced neoangiogenesis
cannot be expected, given the absence of contractile cells
in the scar.
On the other hand, paracrine mechanisms have been
suggested to contribute to the beneficial effects of pro-
genitor cell application after MI [44, 45]. Interestingly,
the application of both, MN-CBS as well as of USSCs
after MI attenuated the expression of ECM components
(Fig. 7) pointing to such indirect mechanisms even in the
absence of regeneration and even 12 weeks after the
injury. Notably, this was observed in the infarct scar only
and only after permanent coronary artery occlusion.
Moreover, the induction of ECM expression after MI was
attenuated to levels comparable to that after I/R, but did
not translate into functional improvement. This might des-
ignate the critical importance of the time of cell injection
after injury. Since labeled injected cells were detected at
6 d after I/R (Fig. 4), it might be speculated that the sub-
stantial differences in the pathomechanisms after per-
manent occlusion and I/R may also require different strat-
egies for cell therapy. The fact that USSCs administered
after I/R led to increased expression of IL-6, but not of
IL-1β in the infarct and the peri-infarct (Fig. 9), further
suggests paracrine effects after cell therapy.
It has now been accepted that the infarct scar is a
highly dynamic tissue for months and even years after
MI in rodents and men [27, 46, 47]. Myofibroblasts are
the main mediators of fibrogenesis and remodeling after
myocardial injury [48], but may also serve as precursor
cells necessary for angiogenesis [49] and, therefore, are
essential for the capacity of the infarcted heart to heal.
Recently, a high number of eGFP positive fibroblasts and
myofibroblasts were observed in the infarct and peri-inf-
arct in a mouse model of MI after BM replacement by
eGFP expressing cells. This suggests that BM derived
myofibroblasts may be of particular importance for the
benefit of BM cells in myocardial healing processes [34].
A recent report, on the other hand, did not show differen-
tiation of BM derived cells into myofibroblasts [50].
Myofibroblast-like cells were observed in the infarct area
of both, cell and medium treated MI hearts (Fig. 6), but
not quantified. Since the injected cells were not labeled
and also screening for human chromosome by FISH was
not done, it remains to be elucidated, if injected cells di-
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rectly take part in remodeling by transformation into
myofibroblasts or rather indirectly modulate the
remodeling by paracrine mechanisms like the expression
of cytokines and growth factors. It should be pointed out
that rats injected with inactive cells after MI would be
the more appropriate controls to test for released factors
or the induction of active processes within the injured
tissue. However, the data on TGF-β expression indicate
differential effects induced by MN-CBCs and USSCs
(Fig. 8). This also indicates that additional factors differ-
ent from TGF-β seem to be important for cardiac
remodeling after MI.
In summary, this study indicates that cord blood cell
implantation after myocardial infarction acts trough
paracrine mechanisms to modify remodeling rather than
myocyte regeneration. The role of myofibroblasts and
the optimal conditions of cell application need to be de-
termined to translate these mechanisms into functional
improvement.
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